Understand the source comparison
Tesofensine Appetite Suppression Research: Comparison Across Mechanisms
Tesofensine Triple monoamine reuptake inhibitor (DAT/SERT/NET) 30–40% reduction in hunger scores 10.6% (1.0mg dose) +7 bpm heart rate, +6–8 mmHg BP Available through specialised peptide suppliers like Real Peptides Semaglutide GLP-1 receptor agonist (slows gas
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Tesofensine
- Triple monoamine reuptake inhibitor (DAT/SERT/NET)
- 30–40% reduction in hunger scores
- 10.6% (1.0mg dose)
- +7 bpm heart rate, +6–8 mmHg BP
- Available through specialised peptide suppliers like Real Peptides
- Semaglutide
- GLP-1 receptor agonist (slows gastric emptying)
- 40–50% reduction via delayed satiety
- 14.9% (2.4mg weekly)
- Minimal. No significant HR or BP changes
- Prescription required; compounded versions available
- Lorcaserin
- 5-HT2C receptor agonist (withdrawn 2020)
- 20–25% reduction via POMC activation
- 5.8% average
- Withdrawn due to cancer signal in long-term data
- No longer available
- Phentermine
- Norepinephrine release agent
- 25–35% reduction (tolerance develops)
- 7–9% (short-term only)
- +10–15 bpm, significant hypertension risk
- Prescription DEA Schedule IV
- Dihexa
- Hepatocyte growth factor (HGF) mimetic
- Indirect. Improves insulin sensitivity
- Not primarily a weight loss compound
- Minimal cardiovascular effect
- Research-grade available via Real Peptides Dihexa